Clinical Trials

MainTitle

A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long‐Acting Nanosuspension of Rilpivirine on Pharmacokinetics

This study has been completed
Sponsor
Janssen Infectious Diseases BVBA


Information provided by (Responsible Party)
Janssen Infectious Diseases BVBA
ClinicalTrials.gov Identifier
NCT02547870

First received: September 10, 2015
Last updated: July 5, 2016
Last Verified: July 2016
History of Changes
Purpose

Purpose

The purpose of this study is to compare the single‐dose pharmacokinetics of rilpivirine (RPV) after intramuscular (IM) injection of rilpivirine long‐acting parenteral formulation (RPV‐LA) and 'aged' RPV‐LA, in healthy adult participants.

Condition Intervention Phase
Human Immunodeficiency Virus Type 1

Drug : Rilpivirine (RPV)
Drug : Rilpivirine Long-Acting Parenteral Formulation (RPV‐LA)
Drug : Aged RPV‐LA
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Open‐Label, Randomized, Parallel‐Group Study in Healthy Subjects to Investigate the Effect of Different Storage Conditions of a Long‐Acting Nanosuspension of Rilpivirine on the Single‐Dose Plasma Pharmacokinetics of Rilpivirine After Intramuscular Injection

Further study details as provided by Janssen Infectious Diseases BVBA:

Primary Outcome Measures

  • Maximum Observed Plasma Concentration (Cmax) [ Time Frame: In session1: Pre‐dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 16, 24, 48, 72, 120 and 168 hours post‐dose; In session 2: Pre‐dose, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168,216, 264, 336, 408, 528, 672, 1344, 2016, 2688, 3360 and 4032 hours post‐dose ]
    The Cmax is the maximum observed plasma concentration of rilpivirine.
  • Area Under the Plasma Concentration‐Time Curve From Time Zero (Day 1) to Day 28 (AUC[0‐d28]) [ Time Frame: In session1: Pre‐dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 16, 24, 48, 72, 120 and 168 hours post‐dose; In session 2: Pre‐dose, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120 and 168 hours post‐dose ]
    The AUC (0‐d28) is the area under the plasma concentration‐time curve for rilpivirine from time zero to day 28.
  • Area Under the Plasma Concentration‐Time Curve From Time Zero to Last Quantifiable Time (AUC [0‐last]) [ Time Frame: In session1: Pre‐dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 16, 24, 48, 72, 120 and 168 hours post‐dose; In session 2: Pre‐dose, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168,216, 264, 336, 408, 528, 672, 1344, 2016, 2688, 3360 and 4032 hours post‐dose ]
    The AUC (0‐last) is the area under the plasma concentration‐time curve for rilpivirine from time zero to last quantifiable time.
  • Area Under the Plasma Concentration‐Time Curve From Time Zero to Infinite Time (AUC[0‐infinity]) [ Time Frame: In session1: Pre‐dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 16, 24, 48, 72, 120 and 168 hours post‐dose; In session 2: Pre‐dose, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168,216, 264, 336, 408, 528, 672, 1344, 2016, 2688, 3360 and 4032 hours post‐dose ]
    The AUC (0‐infinity) is the area under the plasma concentration‐time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentrationtime curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.
Secondary Outcome Measures:
  • Number of Participants With Adverse Events [ Time Frame: Up to 180 Days ]
    An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
  • Time to reach the maximum observed plasma concentration (Tmax) [ Time Frame: In session1: Pre‐dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 16, 24, 48, 72, 120 and 168 hours post‐dose; In session 2: Pre‐dose, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168,216, 264, 336, 408, 528, 672, 1344, 2016, 2688, 3360 and 4032 hours post‐dose ]
    The Tmax is the actual sampling time to reach maximum observed plasma concentration of rilpivirine.
  • Elimination Rate Constant (Lambda [z]) of rilpivirine [ Time Frame: In session1: Pre‐dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 16, 24, 48, 72, 120 and 168 hours post‐dose; In session 2: Pre‐dose, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168,216, 264, 336, 408, 528, 672, 1344, 2016, 2688, 3360 and 4032 hours post‐dose ]
    The Lambda (z) determined by linear regression of the terminal points of the ln‐linear plasma concentration‐time curve.
  • Apparent Terminal Half‐life (t[1/2]) of rilpivirine [ Time Frame: In session1: Pre‐dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 16, 24, 48, 72, 120 and 168 hours post‐dose; In session 2: Pre‐dose, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168,216, 264, 336, 408, 528, 672, 1344, 2016, 2688, 3360 and 4032 hours post‐dose ]
    Apparent terminal elimination half‐life, calculated as 0.693/Lambda (z).

Enrollment: 74
Study Start Date: August 2015
Study Completion Date: April 2016
Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: Rilpivirine Long-Acting Parenteral Formulation (RPV‐LA)
Participants will receive oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1 and intramuscular (IM) injection of rilpivirine long‐acting parenteral formulation 600 mg once on day 1 of session 2.
Drug: Rilpivirine (RPV)

Participants will receive one oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1.

Drug: Rilpivirine Long-Acting Parenteral Formulation (RPV‐LA)

Participants will receive one intramuscular (IM) injection of rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.

Experimental: Aged RPV‐LA
Participants will receive oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1 and IM injection of aged rilpivirine long‐acting parenteral formulation 600 mg once on day 1 of session 2.
Drug: Rilpivirine (RPV)

Participants will receive one oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1.

Drug: Aged RPV‐LA

Participants will receive one intramuscular (IM) injection of aged rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.

Detailed Description:

This is a phase 1 randomized (study medication is assigned by chance), open‐label (all people know the identity of the intervention), parallel‐group, sequential study in healthy adult participants to investigate the effect of different storage conditions for RPV‐LA on the single‐dose pharmacokinetics of rilpivirine (RPV) after intramuscular injection. A total of 60 healthy adult participants will be enrolled in this study. The study will consist of 2 treatment sessions in a fixed sequential order : session 1 of up to day 8, all participants will receive a single oral dose of rilpivirine 25 milligram (mg) tablet on day 1, session 2 will consists of 2 treatment groups. The participants will be randomized in session 2 on Day 1 in a 1:1 ratio to Treatments A and B. Each treatment group will receive one IM injection of RPV LA on Day 1 of session 2. Session 1 and 2 will be separated by a washout period of at least 14 days. The total study duration for each participant will be approximately 6.5 months. Safety will be monitored throughout the study.

Eligibility

Eligibility

Ages Eligible for Study: 18 Years to 55 Years  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: Yes  

Criteria

Inclusion Criteria:

  • Each participant must sign an Informed Consent Form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and are willing to participate in the study
  • Participant must be willing and able to adhere to the prohibitions and restrictions specified in this protocol
    • Participant must be healthy on the basis of a medical evaluation that reveals the absence of any clinically significant abnormality and includes a physical examination, medical history, vital signs, Electrocardiogram (ECG), and the results of blood biochemistry, hematology and coagulation tests and a urinalysis performed at Screening
    • A female participant of childbearing potential must have a negative serum (beta‐human chorionic gonadotropin [beta‐hCG]) at Screening and a negative urine pregnancy test on day 1
    • Participant must be non‐smoking for at least 3 months prior to selection


    Exclusion Criteria:
  • Female participant who is breastfeeding at Screening
    • Participants with a history of any illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant or that could prevent, limit or confound the protocol specified assessments. This may include, but is not limited to, renal dysfunction, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, neoplastic, or metabolic disturbances
    • Has known allergies, hypersensitivity, or intolerance to rilpivirine (RPV) or its excipients
    • Has a history of drug allergy such as, but not limited to, sulfonamides and penicillins, or drug allergy witnessed in previous studies with experimental drugs
    • Having donated or lost more than 1 unit of blood (500 milliliter [mL]) within 60
    days or more than 1 unit of plasma within 7 days before the first dose of study drug

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02547870

Locations

Belgium
Antwerp, Belgium

Sponsors and Collaborators

Janssen Infectious Diseases BVBA

Investigators

Study Director: Janssen Infectious Diseases BVBA Clinical Trial Janssen Infectious Diseases BVBA
More Information

More Information


Responsible Party: Janssen Infectious Diseases BVBA  
ClinicalTrials.gov Identifier: NCT02547870   History of Changes  
Other Study ID Numbers: CR107976  
  TMC278LAHTX1001  
  2015-002259-92  
Study First Received: September 10, 2015  
Last Updated: July 5, 2016  

Keywords provided by Janssen Infectious Diseases BVBA:

Rilpivirine
Healthy participants

Additional relevant MeSH terms:
Immunologic Deficiency Syndromes
Acquired Immunodeficiency Syndrome
HIV Infections
Rilpivirine

ClinicalTrials.gov processed this data on December 15, 2017
This information is provided by ClinicalTrials.gov.